@Article{,
AUTHOR = {E. David Crawford, David Albala, Marc B. Garnick, Andrew W. Hahn, Paul Maroni, Rana R. McKay, Martin Miner, Peter Orio III, Kshitij Pandit, Scott Sellinger, Evan Y. Yu, Robert H. Eckel},
TITLE = {Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {31},
YEAR = {2024},
NUMBER = {2},
PAGES = {11820--11825},
URL = {http://www.techscience.com/CJU/v31n2/59595},
ISSN = {1488-5581},
ABSTRACT = {<b>Introduction:</b> Risk of cardiovascular disease is higher
among men with prostate cancer than men without,
and prostate cancer treatments (especially those that
are hormonally based) are associated with increased
cardiovascular risk.<br/>
<b>Materials and methods:</b> An 11-member panel of
urologic, medical, and radiation oncologists (along
with a men’s health specialist and an endocrinologist/
preventive cardiologist) met to discuss current practices
and challenges in the management of cardiovascular
risk in prostate cancer patients who are taking androgen
deprivation therapies (ADT) including LHRH analogues,
alone and in combination with androgen-targeted
therapies (ATTs).<br/>
<b>Results:</b> The panel developed an assessment algorithm
to categorize patients by risk and deploy a risk
adapted management strategy, in collaboration with
other healthcare providers (the patient’s healthcare
"village"), with the goal of preventing as well as reducing
cardiovascular events. The panel also developed a patient
questionnaire for cardiovascular risk as well as a checklist
to ensure that all aspects of cardiovascular disease risk
reduction are completed and monitored.<br/>
<b>Conclusions:</b> Prostate cancer patients receiving ADT
with or without ATT need to be more zealously assessed
for prevention and aggressively managed to reduce
cardiovascular events. This can and should include
participation from the entire multidisciplinary healthcare
team.},
DOI = {}
}